The effect of hepatocyte growth factor on intestinal adaption in an experimental model of short bowel syndrome
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Jan 2023 · 1 min read
In brief
In brief
This rat model study demonstrates that hepatocyte growth factor (HGF) significantly enhances intestinal adaptation in short bowel syndrome by increasing villus height, crypt depth, and enterocyte proliferation. HGF treatment upregulated key genes in adaptation pathways, suggesting potential to reduce parenteral nutrition dependence in SBS patients.
Written by the GCMD Library team from the article.
Abstract
Purpose
Nowadays, the standard therapy for patients with short bowel syndrome is parenteral nutrition (PN). Various growth factors have been tested to achieve weaning from prolonged PN administration. We evaluated the effect of hepatocyte growth factor (HGF) on structural intestinal adaptation and cell proliferation in a rat model of SBS.
Methods
Thirty Sprague–Dawley rats were divided into three groups; group A rats (sham) underwent bowel transection, group B rats underwent a 75% bowel resection, and group C rats underwent the same procedure but were treated postoperatively with HGF. Histopathologic parameters of intestinal adaptation were determined, while microarray and rt-PCR analyses of ileal RNA were also performed.
Results
Treatment with HGF resulted in significant increase in body weight, while the jejunal and ileal villus height and crypt depth were increased in HGF rats (36%, p < 0.05 and 27%, p < 0.05 respectively). Enterocyte proliferation was also significantly increased in HGF rats (21% p < 0.05). Microarray and quantitative rt-PCR analyses showed that the genes hgfac, rac 1, cdc42, and akt 1 were more than twofold up-regulated after HGF treatment.
Conclusion
HGF emerges as a growth factor that enhances intestinal adaptation. The future use of HGF may potentially reduce the requirement for PN in SBS patients.